Shoulder calcification type and shockwave outcomes · Comparison study · 2019
Does the type of shoulder calcium deposit affect shockwave results?
In this study, everyone had one high-energy shockwave session. A year later, pain had eased in all three groups, most in people whose deposits looked less dense on X-ray: 14 of 20 improved by more than 80%, compared with 5 of 20 with dense deposits and 3 of 20 with no deposit.
Improved over time; best with less dense deposits- people with long-lasting shoulder tendon pain
- 60
- high-energy shockwave session
- 1
- months of follow-up
- 12
Good to know: No group went without shockwave.
Wu KT, Chou WY, Wang CJ, et al. Biomed Res Int, 2019 · Read the paper ↗
How this study worked
What happened
Shoulder pain by deposit type
0–10 pain scale · start and after 12 months
StartAfter 12 months
Show the numbers
| Group | People | Start | After 12 months |
|---|---|---|---|
| No calcium deposit | 20 | 5.5 | 2.9 |
| Less dense deposit | 20 | 5.4 | 1.5 |
| Dense deposit | 20 | 5.4 | 3.8 |
The treatment
No calcium deposit
Focused, 1 session
- Sessions
- 1
- Pulses
- 3,000 per session
- Strength
- 0.32mJ/mm²
- Numbing
- None
- Device
- Ossatron or Orthospec
Less dense deposit
Focused, 1 session
- Sessions
- 1
- Pulses
- 3,000 per session
- Strength
- 0.32mJ/mm²
- Numbing
- None
- Device
- Ossatron or Orthospec
Dense deposit
Focused, 1 session
- Sessions
- 1
- Pulses
- 3,000 per session
- Strength
- 0.32mJ/mm²
- Numbing
- None
- Device
- Ossatron or Orthospec
Compared with: No untreated group; the three groups differed only in the type of deposit
Settings are what each study used, not a prescription.
Who took part
60 people with shoulder tendon pain for over 6 months despite at least 3 months of other care: 20 with no deposit, 20 with less dense and 20 with dense deposits.
Side effects
The study does not report side effects.
All the numbers and the full appraisal
The results, in numbers.
Shoulder tendinosis symptomatic >6 months despite ≥3 months conservative care. Full-thickness tears and type II/III acromia were excluded. Groups: noncalcific NCTS, dense type I DCTS and translucent type II/III TCTS. DCTS symptom duration remained longer after matching (20.3 vs 9.8 months for TCTS).
Source reports this participant group.
Source reports this participant group.
Source reports this participant group.
Pain VAS1 reported outcome
Pain VAS
Pain VAS points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 5.5 (SD 0.76) | 2.9 (SD 2.86) |
| Type II/III | 20 | 5.4 (SD 1.04) | 1.5 (SD 2.48) |
| Type I | 20 | 5.4 (SD 0.94) | 3.8 (SD 2.46) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Across three morphology groups
Kruskal-Wallis
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Constant-Murley total1 reported outcome
Constant-Murley total
Constant-Murley total points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 52.5 (SD 14.5) | 78.7 (SD 18.3) |
| Type II/III | 20 | 49.7 (SD 9.03) | 86.9 (SD 19.7) |
| Type I | 20 | 53.8 (SD 7.66) | 71.1 (SD 17.8) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
CMS pain subscore1 reported outcome
CMS pain subscore
CMS pain subscore points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 4.6 (SD 0.88) | 7.7 (SD 2.13) |
| Type II/III | 20 | 4.1 (SD 1) | 8.8 (SD 2) |
| Type I | 20 | 4.6 (SD 0.6) | 6.5 (SD 2.16) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
CMS night pain1 reported outcome
CMS night pain
CMS night pain points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 2.6 (SD 0.83) | 4.2 (SD 1.04) |
| Type II/III | 20 | 2.6 (SD 0.94) | 4.3 (SD 1.13) |
| Type I | 20 | 2.6 (SD 0.5) | 3.3 (SD 1.2) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
CMS strength1 reported outcome
CMS strength
CMS strength points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 12.6 (SD 3.66) | 19.2 (SD 5.22) |
| Type II/III | 20 | 11.2 (SD 3.23) | 22.4 (SD 5.1) |
| Type I | 20 | 12.7 (SD 3.08) | 18.4 (SD 4.69) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
CMS activity1 reported outcome
CMS activity
CMS activity points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 10.8 (SD 3.16) | 16.1 (SD 4.16) |
| Type II/III | 20 | 10 (SD 2.51) | 17.6 (SD 4.24) |
| Type I | 20 | 10.7 (SD 2.56) | 14.7 (SD 4.13) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
CMS motion1 reported outcome
CMS motion
CMS motion points
| Group | n | Baseline | Follow-up |
|---|---|---|---|
| Noncalcific | 20 | 22 (SD 8.41) | 31.7 (SD 7.18) |
| Type II/III | 20 | 21.9 (SD 7.99) | 33.9 (SD 7.77) |
| Type I | 20 | 23.3 (SD 5.2) | 28.3 (SD 7.06) |
SD: standard deviation. CI: confidence interval. IQR: interquartile range. —: not extracted.
Reported group means; within-group change is not a between-group treatment effect.
Analysis details and source
Mean ± SD as printed. No effect or confidence interval reconstructed.
Complaint-free1 reported outcome
Complaint-free
people
Improvement >80%, not necessarily zero symptoms.
Analysis details and source
Descriptive source-reported counts; no effect estimate reconstructed.
How treatment was delivered
One high-energy electrohydraulic treatment with Ossatron or Orthospec, 3,000 impulses at 0.32 mJ/mm², without anesthesia/analgesics. Image-guided deposit targeting or maximum tenderness for noncalcific disease; supine/sitting.
No structured adverse-event results are provided. The lack of a safety table cannot establish absence of harms.
Small retrospective matched subset, no sham, residual duration imbalance and incomplete imaging follow-up. Table 2 versus text p-values conflict: CMS .007/.014, pain subscore .004/.008, strength .002/.004. Table 1 TCTS age SD 93.58 and Table 2 activity range exceeding specified maximum are source errors requiring clarification. No conflicts declared; biostatistics support acknowledged.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Small retrospective matched subset, no sham, residual duration imbalance and incomplete imaging follow-up. Table 2 versus text p-values conflict: CMS .007/.014, pain subscore .004/.008, strength .002/.004. Table 1 TCTS age SD 93.58 and Table 2 activity range exceeding specified maximum are source errors requiring clarification. No conflicts declared; biostatistics support acknowledged.
Source-linked critical reading
nonrandom comparative
Technical source record
Complete local PDF text read, including all article body sections, tables, figure captions, discussion, disclosures and references. The paper cites no supplementary material.
Translucent deposits were associated with better outcomes after treatment. The study does not show that shockwaves outperform no treatment or that dense/noncalcific cases should automatically receive another procedure.
Do radiographic calcification types predict different outcomes after the same shoulder ESWT?
Retrospective propensity-matched comparison: 60 of 291 treated patients from 1998–2015, 20 per morphology group. All received ESWT; matching was on age, sex, baseline pain and function, not randomized treatment.
Shoulder tendinosis symptomatic >6 months despite ≥3 months conservative care. Full-thickness tears and type II/III acromia were excluded. Groups: noncalcific NCTS, dense type I DCTS and translucent type II/III TCTS. DCTS symptom duration remained longer after matching (20.3 vs 9.8 months for TCTS).
One high-energy electrohydraulic treatment with Ossatron or Orthospec, 3,000 impulses at 0.32 mJ/mm², without anesthesia/analgesics. Image-guided deposit targeting or maximum tenderness for noncalcific disease; supine/sitting.
Morphology groups received the same intervention. NSAIDs, aspirin and physiotherapy were stopped 2 weeks before and 4 weeks after. No untreated or sham comparison.
VAS and Constant-Murley total/subscores before and 3, 6 and 12 months; primary extracted comparison at 12 months. Satisfaction categories used >80%, 50–79%, 25–49% and <24% symptom improvement.
At 12 months VAS NCTS/TCTS/DCTS=2.9/1.5/3.8; CMS=78.7/86.9/71.1. Complaint-free counts 3/20, 14/20, 5/20. Night-pain and activity scores were similar between NCTS and TCTS, both better than DCTS. Results suggest morphology-associated prognosis, not proof of treatment efficacy.
No structured adverse-event results are provided. The lack of a safety table cannot establish absence of harms.
Small retrospective matched subset, no sham, residual duration imbalance and incomplete imaging follow-up. Table 2 versus text p-values conflict: CMS .007/.014, pain subscore .004/.008, strength .002/.004. Table 1 TCTS age SD 93.58 and Table 2 activity range exceeding specified maximum are source errors requiring clarification. No conflicts declared; biostatistics support acknowledged.
For refractory shoulder symptoms, calcification morphology may inform prognosis. Natural resorption of type II/III deposits and unmeasured factors prevent assigning the observed advantage to ESWT alone.
A morphology-stratified sham-controlled trial with prospective imaging and validated outcome reporting is needed; reconcile the table/text inconsistencies first.
Read the original article.
Efficacy of Extracorporeal Shockwave Therapy on Calcified and Noncalcified Shoulder Tendinosis: A Propensity Score Matched Analysis
Wu KT, Chou WY, Wang CJ, Chen CY, Ko JY, Chen PC, Cheng JH, Yang YJ. · Biomed Res Int · 2019
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →